Prakt. Lékáren. 2017; 13(2e) [Psychiatr. praxi 2017; 18(1): 7-10]

Research of new drugs for Alzheimer’s disease

Jana Hroudová

Psychiatrická klinika, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze

Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze

Oddělení klinické farmakologie, VFN v Praze

Alzheimer’s disease (AD) is the most common cause of dementia, however, the treatment AD options are limited and based on administrationof cholinesterase inhibitors and/or memantine, affecting glutamatergic system. Presented review article summarizes current approaches in theresearch of novel agents for AD treatment; it is focused on the molecules reaching the clinical trials. The most developed direction of pharmacotherapyis focused on pathologic β-amyloid (Aβ). Several perspective studies testing monoclonal Aβ antibodies and β-secretase inhibitors are ongoing. Further, new cholinesterase inhibitors, monoamine oxidase inhibitors, anti-tau immunotherapy, agents affecting serotonin andnicotine receptors, antioxidants, and others are developed.

Keywords: Alzheimer’s disease, cholinesterase inhibitors, anti-amyloid beta immunotherapy, beta secretase inhibitors, monoamine oxidase inhibitors

Published: July 1, 2017  Show citation